Skip to main content

Table 4 Summary of QTcB (milliseconds) during the study period

From: 2-deoxy-d-glucose as an adjunct to standard of care in the medical management of COVID-19: a proof-of-concept and dose-ranging randomised phase II clinical trial

 

2-DG 63 mg + SOC

SOC1

2-DG 90 mg + SOC

2-DG 126 mg + SOC

SOC2

Baseline

N

22

21

22

21

18

Mean (SD)

407.0 (32.79)

412.5 (29.45)

429.0 (27.15)

428.6 (21.21)

418.9 (33.06)

Median

409.5

413.0

430.0

423.0

431.5

Day 3

N

22

22

20

21

21

Mean (SD)

419.1 (24.46)

412.5 (24.19)

425.7 (32.72)

427.5 (29.36)

427.0 (22.31)

Median

413.0

406.5

423.0

427.0

421.0

Day 7

N

19

19

10

15

12

Mean (SD)

415.7 (21.86)

412.0 (31.39)

433.5 (30.25)

446.7 (61.33)

411.8 (28.40)

Median

422.0

408.0

423.0

444.0

411.5

End of Treatment

N

22

22

19

21

19

Mean (SD)

413.1 (24.69)

410.4 (20.61)

433.9 (37.82)

435.2 (36.59)

422.4 (23.20)

Median

417.0

411.0

423.0

440.0

422.0

  1. 2-DG 2-deoxy-d-glucose, SOC standard of care, SOC1 SOC in Part A of the study, SOC2 SOC in Part B of the study